Influence of gonadotropin-releasing hormone agonist on the effect of chemotherapy upon ovarian cancer and the prevention of chemotherapy-induced ovarian damage: An experimental study with nu/nu athymic mice

Journal of Zhejiang University: Science B

Volumn 13, Issue 11, 2012, Pages 894-903

  Lin, Qiong Yan ^a   Wang, Yi Feng ^b   Weng, Hui Nan ^a   Sheng, Xiu Jie ^a   Jiang, Qing Ping ^a   Yang, Zhi Ying ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Animal experiment; Cisplatin; Gonadotrophin releasing hormone; Ovarian cancer

Indexed keywords

CASPASE 3; CISPLATIN; EOSIN; HEMATOXYLIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KI 67 ANTIGEN; MUELLERIAN INHIBITING FACTOR; TRIPTORELIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER TISSUE; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HORMONE BLOOD LEVEL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; OVARY; OVARY CANCER; OVARY DISEASE; OVARY FOLLICLE; PRIMORDIAL GERM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; THERAPY EFFECT; TRANSMISSION ELECTRON MICROSCOPY; UTERUS;

ANIMALS; ANTI-MULLERIAN HORMONE; ANTINEOPLASTIC AGENTS; CASPASE 3; CELL LINE, TUMOR; CISPLATIN; CYSTADENOCARCINOMA, SEROUS; DRUG INTERACTIONS; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MICE; MICE, NUDE; MICROSCOPY, ELECTRON, TRANSMISSION; NF-KAPPA B; OVARIAN NEOPLASMS; OVARY; RANDOM ALLOCATION; TRIPTORELIN PAMOATE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA; MUS;

EID: 84869180257     PISSN: 16731581     EISSN: 18621783     Source Type: Journal    
DOI: 10.1631/jzus.B1100369     Document Type: Article

References (33)

1. Arencibia, J.M., Schally, A.V., 2000. Luteinizing hormonereleasing hormone as an autocrine growth factor in ES-2 ovarian cancer cell line. Int. J. Oncol., 16(5):1009-1013.
2. Asschert, J.G., Vellenga, E., Ruiters, M.H., de Vries, E.G., Asschert, J.G., Vellenga, E., Ruiters, M.H., 1999. Regulation of spontaneous and TNF/IFN-induced IL-6 expression in two human ovarian-carcinoma cell lines. Int. J. Cancer, 82(2):244-249. [doi:10.1002/(SICI)1097-0215 (19990719)82:2<244:: AID-IJC15>3.0.CO;2-N] (Pubitemid 29293784)
3. Bours, V., Dejardin, E., Goujon-Letawe, F., Merville, M.P., Castronovo, V., 1994. The NF-κB transcription factor and cancer: high expression of NF-κB and IκB related proteins in tumor cell lines. Biochem. Pharmacol., 47(1):145-149. [doi:10.1016/0006-2952(94)90448-0] (Pubitemid 24045827)
4. Carter, B.D., Kaltschmidt, C., Kaltschmidt, B., Offenhäuser, N., Böhm-Matthaei, R., Baeuerle, P.A., Barde, Y.A., 1996. Selective activation of NF-κB by nerve growth factor through the neurotrophin receptor p75. Science, 272(5261):542-545. [doi:10.1126/science.272.5261.542] (Pubitemid 26138196)
5. Danforth, D.R., Arbogast, L.K., Friedman, C.I., 2005. Acute depletion of murine primordial follicle reserve by gonadotropin-releasing hormone antagonists. Fertil. Steril., 83(5):1333-1338. [doi:10.1016/j.fertnstert.2004. 12.030] (Pubitemid 40615801)
6. Emons, G., Schally, A.V., 1994. The use of luteinizing hormone-releasing ormone agonists and antagonists in gynecological cancers. Hum. Reprod., 9(7):1364-1379. (Pubitemid 24224014)
7. Emons, G., Weiss, S., Ortmann, O., Grundker, C., Schulz, K.D., 2000. Luteinizing hormone-releasing hormone (LHRH) might act as a negative autocrine regulator of proliferation of human ovarian cancer. Eur. J. Endocrinol., 142(6):665-670. [doi:10.1530/eje.0.1420665] (Pubitemid 30399500)
8. Emons, G., Ortmann, O., Teichert, H.M., Fassl, H., Löhrs, U., Kullander, S., Kauppila, A., Ayalon, D., Schally, A., Oberheuser, F., 1996. Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial. Decapeptyl Ovarian Cancer Study Group. Cancer, 78(7):1452-1460. [doi:10.1002/(SICI)1097-0142(19961 001)78:7<1452::AID-CNCR12>3.3.CO;2-5] (Pubitemid 26317866)
9. Enari, M., Sakahira, H., Yokoyama, H., Okawa, K., Iwamatsu, A., Nagata, S., 1998. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature, 391(6662):43-50. [doi:10.1038/34112] (Pubitemid 28079208)
10. Grilli, M., Pizzi, M., Memo, M., Spano, P., 1996. Neuroprotection by aspirin and sodium salicylate through blockade of NF-κB activation. Science, 274(5291):1383-1385. [doi:10.1126/science.274.5291.1383] (Pubitemid 26391464)
11. Grimm, S., Bauer, M.K., Baeuerle, P.A., Schulze-Osthoff, K., 1996. Bcl-2 down-regulates the activity of transcription factor NF-κB induced upon apoptosis. J. Cell Biol., 134(1):13-23. [doi:10.1083/jcb.134.1.13] (Pubitemid 26231517)
12. Gründker, C., Schulz, K., Günthert, A.R., Emons, G., 2000. Luteinizing hormone-releasing hormone induces nuclear factor κB-activation and inhibits apoptosis in ovarian cancer cells. J. Clin. Endocrinol. Metab., 85(10):3815-3820. [doi:10.1210/jc.85.10.3815]
13. Gründker, C., Günthert, A.R., Westphalen, S., Emons, G., 2002a. Biology of the GnRH system in human gynecological cancers. Eur. J. Endocrinol., 146(1):1-14. [doi:10.1530/eje.0.1460001] (Pubitemid 34126412)
14. Gründker, C., Günthert, A.R., Millar, R.P., Emons, G., 2002b. Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation. J. Clin. Endocrinol. Metab., 87(3):1427-1430. [doi:10.1210/jc.87.3.1427] (Pubitemid 36121120)
15. Kang, S.K., Cheng, K.W., Nathwani, P.S., Choi, K.C., Leung, P.C., 2000. Autocrine role of gonadotropin-releasing hormone and its receptor in ovarian cancer cell growth. Endocrine, 13(3):297-304. [doi:10.1385/ENDO:13:3:297] (Pubitemid 32108057)
16. Kim, K.Y., Choi, K.C., Auersperg, N.K., Leung, P.C., 2006. Mechanism of gonadotropin releasing hormone (GnRH)-I and -II-induced cell growth inhibition in ovarian cancer cells: role of the GnRH-I receptor and protein kinase C pathway. Endocr. Relat. Cancer, 13(1):211-220. [doi:10. 1677/erc.1.01033]
17. Imai, A., Takagi, A., Horibe, S., Takagi, H., Tamaya, T., 1998. Evidence for tight coupling of gonadotropin-releasing hormone receptor to stimulated Fas ligand expression in reproductive tract tumors: possible mechanism for hormonal control of apoptotic cell death. J. Clin. Endocrinol. Metab., 83(2):427-431. [doi:10.1210/jc.83.2.427] (Pubitemid 28496517)
18. Imai, A., Ohno, T., Iida, K., Fuseya, T., Furui, T., Tamaya, T., 1994. Gonadotropin-releasing hormone receptor in gynecologic tumors. Frequent expression in adenocarcinoma histologic types. Cancer, 74(9):2555-2561. [doi:10.1002/1097-0142(19941101)74:9<2555::AID-CNCR 2820740925>3.0.CO;2-X] (Pubitemid 24320862)
19. Janssens, R.M., Brus, L., Cahill, D.J., Huirne, J.A., Schoemaker, J., Lambalk, C.B., 2000. Direct ovarian effects and safety aspects of GnRH agonists and antagonists. Hum. Reprod. Update, 6(5):505-518. [doi:10.1093/humupd/6.5.505]
20. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., Thun, M.J., 2008. Cancer statistics, 2008. CA: Cancer J. Clin., 58(2):71-96. [doi:10.3322/CA.2007.0010] (Pubitemid 351521864)
21. Meirow, D., Lewis, H., Nugent, D., Epstein, M., 1999. Subclinical depletion of primordial follicular reserve in mice treated with cyclophosphamide: clinical importance and proposed accurate investigative tool. Hum. Reprod., 14(7):1903-1907. [doi:10.1093/humrep/14.7.1903] (Pubitemid 29358724)
22. Meirow, D., Assad, G., Dor, J., Rabinovici, J., 2004. The GnRH antagonist cetrorelix reduces cyclophosphamideinduced ovarian follicular destruction in mice. Hum. Reprod., 19(6):1294-1299. [doi:10.1093/humrep/deh257] (Pubitemid 38807699)
23. Myers, M., Britt, K.L., Wreford, N.G., Ebling, F.J., Kerr, J.B., 2004. Methods for quantifying follicular numbers within the mouse ovary. Reproduction, 127(5):569-580. [doi:10.1530/rep.1.00095] (Pubitemid 38745074)
24. Pereira, S.G., Oakley, F., 2008. Nuclear factor-kappaB1: regulation and function. Int. J. Biochem. Cell Biol., 40(8):1425-1430. [doi:10.1016/j.biocel. 2007.05.004] (Pubitemid 351626701)
25. Seppänen, M., Henttinen, T., Lin, L., Punnonen, J., Grénman, S., Punnonen, R., Vihko, K.K., 1998. Inhibitory effects of cytokines on ovarian and endometrial carcinoma cells in vitro with special reference to induction of specific transcriptional regulators. Oncol. Res., 10(11-12):575-589. (Pubitemid 128740446)
26. Shibata, S., Sato, H., Ota, H., Karube, A., Takahashi, O., Tanaka, T., 1997. Involvement of annexin V in antiproliferative effects of gonadotropin-releasing hormone agonists on human endometrial cancer cell line. Gynecol. Oncol., 66(2):217-221. [doi:10.1006/gyno.1997.4746] (Pubitemid 27335406)
27. Stoffel, A., Chaurushiya, M., Singh, B., Levine, A.J., 2004. Activation of NF-kappaB and inhibition of p53-mediated apoptosis by API2/mucosa-associated lymphoid tissue 1 fusions promote oncogenesis. PNAS, 101(24):9079-9084. [doi:10.1073/pnas.0402415101] (Pubitemid 38781614)
28. Sun, X.F., Zhang, H., 2007. NF-κB and NF-κBI polymorphisms in relation to susceptibility of tumour and other diseases. Histol. Histopathol., 22(12):1387-1398. (Pubitemid 47470331)
29. Tang, X., Yano, T., Osuga, Y., Matsumi, H., Yano, N., Xu, J., Wada, O., Koga, K., Kugu, K., Tsutsumi, O., et al., 2002. Cellular mechanisms of growth inhibition of human epithelial ovarian cancer cell line by LH releasing hormone antagonist Cetrorelix. J. Clin. Endocrinol. Metab., 87(8):3721-3727. [doi:10.1210/jc.87.8.3721] (Pubitemid 34879518)
30. Völker, P., Gründker, C., Schmidt, O., Schulz, K.D., Emons, G., 2002. Expression of receptors for luteinizing hormone-releasing hormone in human ovarian andendometrial cancers: frequency, autoregulation, and correlation with direct antiproliferative activity of luteinizing hormone-releasing hormone analogues. Am. J. Obstet. Gynecol., 186(2):171-179. [doi:10.1067/mob.2002. 119633] (Pubitemid 34165428)
31. Wang, C.Y., Mayo, M.W., Korneluk, R.G., Goeddel, D.V., Baldwin, A.S.Jr., 1998. NF-kappaB anti-apoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science, 281(5383): 1680-1683. [doi:10.1126/science.281.5383.1680] (Pubitemid 28435585)
32. Wu, M., Lee, H., Ballas, R., 1996. Inhibition of NF-κB/Rel induces apoptosis of murine B cells. EMBO J. 15(17): 4682-4690. (Pubitemid 26294586)
33. Zou, H., Henzel, W.J., Liu, X., Lutschg, A., Wang, X., 1997. A human protein homologues to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell, 90(3):405-413. [doi:10.1016/S0092-8674(00)80501- 2] (Pubitemid 27347231)